1. Scrip
  2. >>Business
  3. >>Financing

ADC-Focused Myricx Moves To Next Phase With £90m Cash Injection

 
• By Kevin Grogan

The UK spin-out from Imperial College London and the Francis Crick Institute has secured a significant series A financing to advance its novel antibody-drug conjugates which it believes offers a highly differentiated profile over standard payload classes.

Myricx
The three founders of Myricx with CEO Robin Carr (r) • Source: Imperial College London, Jason Alden

These are tough times for start-ups to raise cash on this side of the Atlantic but the money is there if you are developing a novel class of payloads in the hot space of antibody-drug conjugates (ADC), Myricx Bio being a prime example.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.